Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D6XS7L
|
|||
| Drug Name |
BMS-986315
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
| Company |
Bristol-Myers Squibb
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NKG2-A/B-activating NK receptor (NKG2A) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Antigen processing and presentation | |||
| Natural killer cell mediated cytotoxicity | ||||
| Graft-versus-host disease | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| WikiPathways | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04349267) Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.